Summary of ADMA Biologics, Inc. (NASDAQ:ADMA) Ratings

ADMA Biologics, Inc. (NASDAQ:ADMA) Corporate Logo
Big Money Sentiment increased to 3.67 in 2018 Q2. It has change of 0.81, from 2018Q1’s 2.86. The ratio is positive due to ADMA Biologics, Inc. positioning: 9 sold and 3 reduced. 27 funds bought holdings and 17 increased holdings. Investors holded 15.52 million in 2018Q1 but now own 46.43 million shares or 199.18% more.
Amp Cap Limited reported 0% stake. Vanguard Gru Incorporated holds 0% or 1.13M shs. Meeder Asset reported 396 shs. Consonance Capital Mgmt L P has invested 1.24% in ADMA Biologics, Inc. (NASDAQ:ADMA). Broadfin Ltd Liability Co stated it has 3.25 million shs or 2.31% of all its holdings. Wells Fargo & Mn has invested 0% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Prelude Cap Mngmt Llc stated it has 58,879 shs. State Street owns 277,005 shs. Savings Bank Of America De holds 0% in ADMA Biologics, Inc. (NASDAQ:ADMA) or 304 shs. Raymond James Financial Advsr reported 0% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). California State Teachers Retirement Systems accumulated 0% or 28,946 shs. Private Advisor Gp Ltd Llc holds 0% in ADMA Biologics, Inc. (NASDAQ:ADMA) or 52,091 shs. Morgan Stanley accumulated 48,180 shs. Aisling Capital Limited Com holds 3.61M shs. Spark Invest Mgmt Ltd has 0.01% invested in ADMA Biologics, Inc. (NASDAQ:ADMA).

ADMA Biologics, Inc. (NASDAQ:ADMA) Ratings Coverage

A total of 6 analysts rate ADMA Biologics (NASDAQ:ADMA) as follows: 6 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:ADMA) has 6 ratings reports on Dec 6, 2018 according to StockzIntelligence. In Thursday, July 26 report Maxim Group maintained the stock with “Buy” rating. On Friday, October 12 the firm has “Outperform” rating given by Raymond James. The stock rating was maintained by Ladenburg with “Buy” on Wednesday, June 13. Listed here are ADMA Biologics, Inc. (NASDAQ:ADMA) PTs and latest ratings.

30/10/2018 Broker: H.C. Wainwright Rating: Buy New Target: $17 Initiates Coverage On
12/10/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $11 New Target: $10 Maintain
30/07/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $10 Initiates Coverage On
26/07/2018 Broker: Maxim Group Old Rating: Hold New Rating: Buy Old Target: $10 New Target: $12 Maintain
13/07/2018 Broker: Oppenheimer Rating: Outperform New Target: $13 Initiates Coverage On
13/06/2018 Broker: Ladenburg Rating: Buy New Target: $7.5000 Maintain

ADMA is hitting $4.97 during the last trading session, after increased 0.61%.Currently ADMA Biologics, Inc. is uptrending after 68.73% change in last December 6, 2017. ADMA has 114,950 shares volume. ADMA outperformed by 53.11% the S&P500.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases.The firm is worth $230.37 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease.Currently it has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

For more ADMA Biologics, Inc. (NASDAQ:ADMA) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Premarket analyst action – healthcare – Seeking Alpha” brought out on July 13, 2018, “Revisiting ADMA Biologics – Seeking Alpha” on August 23, 2018, “ADMA Biologics: Almost Ready To Run Between The Toes Of Giants – Seeking Alpha” with a publish date: March 06, 2018, “IMDZ Discontinues SYNOVATE, FDA Delays Decision On ADMA’s Bivigam, TRVN Snubbed – Nasdaq” and the last “FDA accepts ADMA Bio’s refiled marketing application for RI-002, action date April 2, 2019 – Seeking Alpha” with publication date: October 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.